Patients Less Likely to Stop Taking Tecfidera Than Aubagio: Study

Patients Less Likely to Stop Taking Tecfidera Than Aubagio: Study

299150

Patients Less Likely to Stop Taking Tecfidera Than Aubagio: Study

Tecfidera has a lower risk of discontinuation due to treatment failure than Aubagio in people with multiple sclerosis (MS), a new observational study in Norway suggests. In the study, people receiving Tecfidera (dimethyl fumarate) were 38% less likely to experience treatment failure and stop use than those receiving Aubagio (teriflunomide). The study, “Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis,” was published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical.…

You must be logged in to read/download the full post.